Sonoma Pharmaceuticals, Inc. (SNOA) News

Sonoma Pharmaceuticals, Inc. (SNOA): $1.57

-0.02 (-1.26%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SNOA News Items

SNOA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SNOA News Highlights

  • SNOA's 30 day story count now stands at 2.
  • Over the past 6 days, the trend for SNOA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • EYE, DLA and SKIN are the most mentioned tickers in articles about SNOA.

Latest SNOA News From Around the Web

Below are the latest news stories about SONOMA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SNOA as an investment opportunity.

Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that it has entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of PrimocynTM Skin Solution products

Yahoo | January 31, 2023

NEE Stock Alert: NextEra Energy Announces Leadership Changes

NextEra Energy (NEE) stock is on the move Wednesday after the Florida energy company announced changes to its leadership.

William White on InvestorPlace | January 25, 2023

NWSA Stock Alert: What to Know as Rupert Murdoch Abandons Merger Plans

News Corporation (NWSA) stock is in the news Wednesday after a merger plan between it and Fox Corporation (FOXA,FOX) was terminated.

William White on InvestorPlace | January 25, 2023

Why Is Sonoma Pharmaceuticals (SNOA) Up 70% Today?

Sonoma Pharmaceuticals (SNOA) stock is rocketing higher on Wednesday following positive news for its Microcyn Rx products.

William White on InvestorPlace | January 25, 2023

Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that Microcyn® Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).

Yahoo | January 25, 2023

Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care today announced that it has launched a line of office dispense products exclusively for skin care professionals.

Yahoo | January 4, 2023

Sonoma Pharmaceuticals Second Quarter 2023 Earnings: US$0.33 loss per share (vs US$0.043 loss in 2Q 2022)

Sonoma Pharmaceuticals ( NASDAQ:SNOA ) Second Quarter 2023 Results Key Financial Results Revenue: US$3.33m (down 11...

Yahoo | November 17, 2022

Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced financial results for its second fiscal quarter and six months ended September 30, 2022.

Yahoo | November 14, 2022

Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care and dermatological conditions, today announced that it has launched Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn® Advanced Skin Repair Cooling Mist direct to consumers for

Yahoo | October 27, 2022

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, and dermatological conditions, announced that it will be exhibiting at the CPHI Conference in Frankfurt, Germany on November 1-3, 2022.

Yahoo | October 6, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7021 seconds.